Advanced search
1 file | 1.36 MB

Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer

Elke Van Daele (UGent) , VINCENZO SCUDERI (UGent) , Eva Pape (UGent) , Dirk Van de Putte (UGent) , Oswald Varin (UGent) , Yves Van Nieuwenhove (UGent) , Wim Ceelen (UGent) , Roberto Troisi (UGent) and Piet Pattyn (UGent)
(2018) ACTA CHIRURGICA BELGICA. 118(4). p.227-232
Author
Organization
Abstract
Background and objectives: Esophageal cancer (EC) remains an aggressive disease with a poor survival. Management of metastatic EC is limited to palliative chemotherapy (CT). Scientific contributions regarding the role of surgery are scarce and controversial. We analysed outcome of surgically treated metastatic EC patients. Methods: We retrospectively identified surgically treated metastatic EC patients from our esophagectomy database. The aim of this study was to evaluate surgical complications, pathological response, oncological outcome and mean survival of these aggressively treated stage IV cancer patients. Results: Twelve stage IV patients with disease presentation limited to outfield lymph node (LN) and/or liver metastasis were treated with an aggressive multimodality treatment including surgery. Mean age was 58 years (75% male, 75% Adenocarcinomas). Median postoperative hospital stay was 15 d. Radiological anastomotic leakage occurred in one patient. In hospital, mortality was nil. Complete resection was achieved in all but one. Metastatic recurrence occurred in 64% of RO resected patients. At date of censoring, after a median follow-up of 22 months, 50% of the surgical resected patients are still alive and 33% are free of disease recurrence. Kaplan-Meier curves show a possibility to long-term survival after aggressive multimodality therapy including surgery. Conclusions: In selected metastatic EC patients, multimodality treatment including surgery has an acceptable surgical outcome with a potentially long-term survival.
Keywords
RESECTION, LIVER, CARCINOMA, OUTCOMES, Stage IV esophageal cancer, metastases, metastases, esophagectomy

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.36 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Van Daele, Elke, VINCENZO SCUDERI, Eva Pape, Dirk Van de Putte, Oswald Varin, Yves Van Nieuwenhove, Wim Ceelen, Roberto Troisi, and Piet Pattyn. 2018. “Long-term Survival After Multimodality Therapy Including Surgery for Metastatic Esophageal Cancer.” Acta Chirurgica Belgica 118 (4): 227–232.
APA
Van Daele, Elke, SCUDERI, V., Pape, E., Van de Putte, D., Varin, O., Van Nieuwenhove, Y., Ceelen, W., et al. (2018). Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer. ACTA CHIRURGICA BELGICA, 118(4), 227–232.
Vancouver
1.
Van Daele E, SCUDERI V, Pape E, Van de Putte D, Varin O, Van Nieuwenhove Y, et al. Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer. ACTA CHIRURGICA BELGICA. 2018;118(4):227–32.
MLA
Van Daele, Elke, VINCENZO SCUDERI, Eva Pape, et al. “Long-term Survival After Multimodality Therapy Including Surgery for Metastatic Esophageal Cancer.” ACTA CHIRURGICA BELGICA 118.4 (2018): 227–232. Print.
@article{8583494,
  abstract     = {Background and objectives: Esophageal cancer (EC) remains an aggressive disease with a poor survival. Management of metastatic EC is limited to palliative chemotherapy (CT). Scientific contributions regarding the role of surgery are scarce and controversial. We analysed outcome of surgically treated metastatic EC patients. 
Methods: We retrospectively identified surgically treated metastatic EC patients from our esophagectomy database. The aim of this study was to evaluate surgical complications, pathological response, oncological outcome and mean survival of these aggressively treated stage IV cancer patients. 
Results: Twelve stage IV patients with disease presentation limited to outfield lymph node (LN) and/or liver metastasis were treated with an aggressive multimodality treatment including surgery. Mean age was 58 years (75\% male, 75\% Adenocarcinomas). Median postoperative hospital stay was 15 d. Radiological anastomotic leakage occurred in one patient. In hospital, mortality was nil. Complete resection was achieved in all but one. Metastatic recurrence occurred in 64\% of RO resected patients. At date of censoring, after a median follow-up of 22 months, 50\% of the surgical resected patients are still alive and 33\% are free of disease recurrence. Kaplan-Meier curves show a possibility to long-term survival after aggressive multimodality therapy including surgery. 
Conclusions: In selected metastatic EC patients, multimodality treatment including surgery has an acceptable surgical outcome with a potentially long-term survival.},
  author       = {Van Daele, Elke and SCUDERI, VINCENZO and Pape, Eva and Van de Putte, Dirk and Varin, Oswald and Van Nieuwenhove, Yves and Ceelen, Wim and Troisi, Roberto and Pattyn, Piet},
  issn         = {0001-5458},
  journal      = {ACTA CHIRURGICA BELGICA},
  language     = {eng},
  number       = {4},
  pages        = {227--232},
  title        = {Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer},
  url          = {http://dx.doi.org/10.1080/00015458.2017.1411557},
  volume       = {118},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: